Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Feb. 01, 2025		Feb. 03, 2024
Operating activities
Net (loss) income	$ (19,047,000)		$ 25,446,000
Add (deduct) items not affecting operating cash flows:
Impairment of goodwill	31,973,000	[1]	0
Depreciation and amortization	4,006,000		4,939,000
Allowance for doubtful accounts	9,000		104,000
Gain on sale of intangible assets			(32,808,000)
Gain on sale of subsidiary	(7,634,000)
Loss on disposal of property and equipment	88,000		260,000
Amortization of deferred financing costs	312,000		758,000
Deferred income taxes	(4,282,000)		(4,021,000)
Share-based compensation expense	1,588,000		1,541,000
Capitalized PIK Interest due to loan with former related party	4,515,000		4,026,000
Loss on debt extinguishment			3,136,000
Equity in net income of equity method investment, net of distributions	2,683,000		(121,000)
Changes in assets and liabilities:
Receivables, net	(11,652,000)		(42,000)
Inventories	(376,000)		31,236,000
Prepaid expenses and other current assets	298,000		(655,000)
Accounts payable and accrued expenses	19,820,000		(23,994,000)
Other assets and liabilities	(242,000)		(8,165,000)
Net cash provided by operating activities	22,059,000		1,640,000
Investing activities
Payments for capital expenditures	(4,232,000)		(1,460,000)
Transaction costs related to equity method investment			(525,000)
Proceeds from sale of intangible assets			77,525,000
Net cash (used in) provided by investing activities	(4,232,000)		75,540,000
Financing activities
Proceeds from borrowings under the Revolving Credit Facilities	211,213,000		245,116,000
Repayment of borrowings under the Revolving Credit Facilities	(214,027,000)		(289,387,000)
Repayment of borrowings under the Term Loan Facilities			(29,378,000)
Repayment of borrowings under the Third Lien Credit Facility	(15,000,000)
Tax withholdings related to restricted stock vesting	(264,000)		(142,000)
Proceeds from issuance of common stock under employee stock purchase plan	29,000		48,000
Financing fees	(332,000)		(3,336,000)
Net cash used in financing activities	(18,381,000)		(77,079,000)
(Decrease) increase in cash, cash equivalents, and restricted cash	(554,000)		101,000
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	1,000		2,000
Cash, cash equivalents, and restricted cash, beginning of period	1,219,000		1,116,000
Cash, cash equivalents, and restricted cash, end of period	666,000		1,219,000
Less: restricted cash at end of period	59,000		862,000
Cash and cash equivalents per balance sheet at end of period	607,000		357,000
Supplemental Disclosures of Cash Flow Information
Cash payments for interest	1,784,000		6,400,000
Cash payments for income taxes, net of refunds	25,000		752,000
Supplemental Disclosures of Non-Cash Investing and Financing Activities
Non-cash equity method investment			25,500,000
Deemed contribution in connection with debt extinguishment	11,575,000
Capital expenditures in accounts payable and accrued liabilities	782,000		117,000
Contribution from principal stockholder in accounts receivable	614,000
Deferred financing fees in accrued liabilities	$ 135,000		$ 1,000

[1] (1) Recorded within Impairment of goodwill on the Consolidated Statements of Operations and Comprehensive Income (Loss).